Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
- 1 January 2012
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 302 (2), G225-G235
- https://doi.org/10.1152/ajpgi.00274.2011
Abstract
The aims of this study were designed to determine whether liraglutide, a long-acting glucagon-like peptide, could reverse the adverse effects of a diet high in fat that also contained trans-fat and high-fructose corn syrup (ALIOS diet). Specifically, we examined whether treatment with liraglutide could reduce hepatic insulin resistance and steatosis as well as improve cardiac function. Male C57BL/6J mice were pair fed or fed ad libitum either standard chow or the ALIOS diet. After 8 wk the mice were further subdivided and received daily injections of either liraglutide or saline for 4 wk. Hyperinsulinemic-euglycemic clamp studies were performed after 6 wk, revealing hepatic insulin resistance. Glucose tolerance and insulin resistance tests were performed at 8 and 12 wk prior to and following liraglutide treatment. Liver pathology, cardiac measurements, blood chemistry, and RNA and protein analyses were performed. Clamp studies revealed hepatic insulin resistance after 6 wk of ALIOS diet. Liraglutide reduced visceral adiposity and liver weight ( P < 0.001). As expected, liraglutide improved glucose and insulin tolerance. Liraglutide improved hypertension ( P < 0.05) and reduced cardiac hypertrophy. Surprisingly, liver from liraglutide-treated mice had significantly higher levels of fatty acid binding protein, acyl-CoA oxidase II, very long-chain acyl-CoA dehydrogenase, and microsomal triglyceride transfer protein. We conclude that liraglutide reduces the harmful effects of an ALIOS diet by improving insulin sensitivity and by reducing lipid accumulation in liver through multiple mechanisms including, transport, and increase β-oxidation.Keywords
This publication has 49 references indexed in Scilit:
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting MacroautophagyPLOS ONE, 2011
- Liver fatty acid-binding protein and obesityThe Journal of Nutritional Biochemistry, 2010
- Glucose regulates fatty acid binding protein interaction with lipids and peroxisome proliferator-activated receptor αJournal of Lipid Research, 2010
- Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse modelJournal of Hepatology, 2010
- Impaired Glucose Tolerance and Predisposition to the Fasted State in Liver Glycogen Synthase Knock-out MicePublished by Elsevier BV ,2010
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayHepatology, 2010
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in MiceDiabetes, 2009
- The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin ActionEndocrinology, 2008
- Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver DiseaseSeminars in Liver Disease, 2008
- Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver diseaseJCI Insight, 2007